CooperVision has released its groundbreaking MiSight® 1 day contact lens in Japan, the first product aimed at controlling myopia in children, a pressing issue in the region.

CooperVision Strengthens Global Footprint with Expanded Access to Myopia Management in Asia-Pacific ROCHESTER, N.Y., Feb. 10, 2026 /PRNewswire/ — CooperVision today announced immediate availability of its MiSight® 1 day* myopia control contact lens in Japan, where as many as 77% of elementary school children are estimated to be myopic, equating to millions who could benefit from […]

Dr. Jennifer Lyerly, Dr. Dave Ng, and Dr. Cary Herzberg on choosing between MiSight, ortho-K, atropine, and Stellest — and why you don't need a $40,000 biometer to start.

CooperVision's commitment shines at NCC 2026, demonstrating how evidence-based practices enhance the comfort and clarity of contact lenses for all ages.

CooperVision introduces MyDay® MiSight® 1 Day lenses to help manage myopia in children, expanding their evidence-based portfolio.

CooperVision unveils MyDay® MiSight® 1 day soft contact lenses in the UK, designed for effective myopia management among children using advanced technology.

CooperVision is set to release its new MyDay® MiSight® 1-day contact lenses designed for myopia control, enhancing vision management for children.

CooperVision’s new MyDay® MiSight® 1 Day lenses aim to tackle myopia among children, combining ActivControl® tech and advanced silicone hydrogel material.

CooperVision is set to launch MyDay® MiSight® 1-day contact lenses aimed at controlling myopia in children, leveraging advanced silicone hydrogel material.

CooperVision Strengthens Global Footprint with Expanded Access to Myopia Management in Asia-Pacific ROCHESTER, N.Y., Feb. 10, 2026 /PRNewswire/ -- CooperVision today announced immediate availability of its MiSight® 1 day* myopia control contact lens in Japan, where as many as 77% of...

New Lenses Combine Advanced Silicone Hydrogel Material with Proven ActivControl® Technology*1 to Slow the Worsening of Myopia in Children†2,3 FAREHAM, England, Jan. 6, 2026 /PRNewswire/ -- CooperVision today announced the forthcoming launch of MyDay® MiSight® 1 day contact lenses in the...

The myopia control field stands at an ethical crossroads. Withholding proven soft contact lens interventions in control arms of myopia management trials is increasingly viewed as ethically questionable and operationally challenging, particularly given that MiSight 1-day contact lens has demonstrated efficacy in at least four randomised controlled trials. The recent methodological evolution towards non-inferiority trials against an established control rather than a placebo (single vision) is a welcome change. However, this shift raises a critical challenge: setting non-inferiority margins that are both clinically meaningful and statistically robust.

SIGNIFICANCE: Contact lenses (CLs) utilizing opaque, nonrefractive features may purposefully modulate retinal ganglion cell activity away from the baseline activity. This is a nonrefractive mechanism that may reduce myopia progression. However, the visual performance of CLs with opaque features is unknown. PURPOSE: This study aimed to compare the visual performance and binocular/accommodative function of CLs with opaque features (test) against MiSight (control-1) and single-vision (control-2) CLs. METHODS: This was a prospective, randomized, unmasked, cross-over study where 35 myopic CL wearers (18 to 39 years) wore each design for at least 5 days. Visual performance was subjectively assessed using 1 to 10 numeric ratings comprising clarity of vision, lack of ghosting, vision when driving, overall vision satisfaction, and willingness to purchase (yes/no: based on vision and myopia efficacy). Visual acuity measurements comprised monocular and binocular high and low contrast visual acuity at 6 m, and binocular high contrast visual acuity at 70 and 40 cm. Binocular function was assessed using heterophorias at 3 m and 40 cm. Accommodative function was assessed using monocular accommodative facility (MAF) at 40 cm and dynamic monocular accommodative response (AR: 6 m, 70 cm, and 40 cm). RESULTS: Test was rated higher than control-1 (p0.99). AR was higher with test than both controls at 70 cm (p